Proquad market report points to faster growth in Asia-Pacific

The Business Research Company says the Proquad vaccine market will expand through 2030, driven by rising measles and chickenpox cases, higher immunization spending and wider use of combination vaccines. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Proquad is a combination vaccine for measles, mumps, rubella and varicella, so market growth reflects demand for simpler pediatric immunization schedules and broader disease protection. - Rising measles and chickenpox incidence underscores the need for vaccination programs that can improve coverage and help limit outbreaks. - Higher healthcare spending can expand access to immunization infrastructure, funding and insurance coverage.

What happened: - The Business Research Company published a Proquad market report covering historical trends and forecasts for 2026 to 2030. - The report says North America led the Proquad vaccine market in 2025. - The report says Asia-Pacific is expected to post the fastest growth during 2026 to 2030. - The analysis also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company offered a free sample of the report and a full market report.

The details: - Proquad reduces the number of shots required by combining multiple vaccines into one injection. - The vaccine is primarily given to children, usually as a single dose between 12 months and 12 years of age. - The report says routine childhood vaccination programs, public awareness, pediatric healthcare infrastructure and government-backed immunization funding have supported market growth. - Forecast growth is tied to efforts to raise vaccination coverage, investment in next-generation vaccine development, stronger monitoring of immunization compliance, public-private vaccination partnerships and better distribution logistics. - Expected trends include greater adoption of combination vaccines, broader pediatric coverage, expanded national immunization programs, improved cold chain systems and enhanced vaccine safety monitoring. - The report cites the World Health Organization’s first-quarter 2024 tally of 56,634 measles cases and four deaths across 45 of the 53 countries in the WHO European Region. - The report links higher healthcare spending to stronger vaccine adoption, and cites UK healthcare expenditure of about $362 billion (£292 billion) in 2023, up 5.6% nominally. - The report says UK spending on long-term health and social care rose 2.8% in real terms in 2022. - The 2026 report package includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and technology and future-trend analysis.

Between the lines: - The report frames Proquad as part of a broader shift toward combination vaccines, where health systems look to raise uptake while reducing visit complexity. - The regional split suggests mature markets may continue to lead on size, while faster population growth and expanding immunization programs drive momentum in Asia-Pacific. - The emphasis on cold chain systems and safety monitoring points to execution risks that can shape real-world vaccine adoption.

What's next: - The market will likely track vaccination coverage policies, public health spending and outbreak activity through 2030. - Adoption should depend on how quickly health systems can expand pediatric immunization access and maintain vaccine distribution quality. - The Business Research Company is positioning its updated 2026 reports around deeper market analytics and strategic tools for buyers and operators. - Contact details for the report were included in the release for sales and expert follow-up.